We already have combo. Where the real advance and revenues come is in mono. Even with the stumbling blocks in the interventional trial we did very good. Now that we know what to avoid we'll do better.

Why waste our money doing a two drug combo. Once we're approved other companies will finance their own combo trials just to jump on the bandwagon. As an example look at the feeding frenzy surrounding Keytruda.